Jennifer Taubert

Taubert has seen some ups and downs since taking over J&J’s pharma business in 2018. At $40.7 billion, it accounts for about half of the company’s revenue. Her segment has come under scrutiny for its culpability in the opioid crisis; J&J was ordered to pay a $572 million judgment last month in Oklahoma (those charges predate Taubert’s tenure in the role). The upside: Two new J&J drugs have been approved so far in 2019.

Subscribe to The Broadsheet, our newsletter on the world’s most powerful women.